HanchorBio Inc.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025 2025-12-11 21:00
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 2025-12-08 20:00
HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers 2025-11-07 22:00
HanchorBio Presents Preclinical Data on HCB301 at SITC 2025 2025-11-05 20:00
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity 2025-10-24 07:30
HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology 2025-10-23 19:00
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach 2025-07-01 13:40
1